glp 1 moa GLP-1 Agonists - What is it? GLP1 Receptor Agonists—Effects beyond Obesity

The Regulatory Advantages of Energetic Therapies Unlike compounded GLP-1 medications facing strict FDA regulations, energetic therapies remain fully compliant with FDA guidelines

And weight gain is often driven by multiple factors: hormones, insulin resistance, medications, sleep deprivation, stress, and muscle loss

This medications safety profile has not been studied in patients under the age of 18, pregnant and lactating people, or those with normal BMIs. At the time of publishing, the FDA has only approved three GLP-1 agonists for weight loss: Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide)

Poor nutrition and obesity disproportionately affect individuals with lower socioeconomic status in rural communities and in racial and ethnic minoritized populations [226], and disparities in poor nutrition and obesity prevalence are mirrored in disparities in access to quality health care [227]

Meneghini LF, Hogan AR, Selvaggi G